{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:04:57Z","timestamp":1781327097203,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010849","name":"Health and Family Planning Commission of Wuhan Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.eplepsyres.2020.106485","type":"journal-article","created":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T01:18:53Z","timestamp":1602379133000},"page":"106485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children"],"prefix":"10.1016","volume":"168","author":[{"given":"Maochang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaosong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2020.106485_bib0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jsps.2019.04.009","article-title":"Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility","volume":"27","author":"Al-Eitan","year":"2019","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FPC.0000000000000000","article-title":"GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures","volume":"23","author":"Balan","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","article-title":"Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays","volume":"320","author":"Baltes","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10072-018-3308-3","article-title":"Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis","volume":"39","author":"Bao","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2017.07.007","article-title":"The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy","volume":"51","author":"Bertok","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0040","first-page":"279","article-title":"ABCC2 rs2273697 is associated with valproic acid concentrations in patients with epilepsy on valproic acid monotherapy","volume":"73","author":"Chen","year":"2018","journal-title":"Pharmazie"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.dmpk.2018.01.006","article-title":"Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy","volume":"34","author":"Chen","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12883-017-0801-x","article-title":"Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis","volume":"17","author":"Chouchi","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0055","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0006-2952(03)00076-5","article-title":"The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases","volume":"65","author":"Ethell","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0060","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/FTD.0000000000000337","article-title":"Effects of UGT1A6 and GABRA1 on standardized valproic acid plasma concentrations and treatment effect in children with epilepsy in China","volume":"38","author":"Feng","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.seizure.2018.04.006","article-title":"Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures","volume":"58","author":"Feng","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0075","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/epi.12132","article-title":"A systematic review and meta-analysis of the role of ABCC2 variants on drug response in patients with epilepsy","volume":"54","author":"Grover","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0080","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.biochi.2010.04.008","article-title":"Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients","volume":"92","author":"Grover","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0085","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0090","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2217\/pgs.12.127","article-title":"SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study","volume":"13","author":"Haerian","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0095","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/pgs.13.104","article-title":"SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis","volume":"14","author":"Haerian","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/FPC.0b013e3283117d67","article-title":"Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression","volume":"18","author":"Kwan","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0115","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2217\/pgs-2016-0093","article-title":"Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese","volume":"17","author":"Li","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0120","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8096235","article-title":"Association of SCN1A, SCN2A, and UGT2B7 polymorphisms with responsiveness to valproic acid in the treatment of epilepsy","volume":"2020","author":"Lu","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0125","first-page":"89","article-title":"Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients","volume":"14","author":"Maleki","year":"2010","journal-title":"Iran. Biomed. J."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1570159X15666171109143654","article-title":"Relevance of CYP2C9 function in valproate therapy","volume":"17","author":"Monostory","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0135","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Moshe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0140","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1755-5949.2012.00336.x","article-title":"ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients","volume":"18","author":"Qu","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0150","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2009.12.004","article-title":"Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy","volume":"19","author":"Sanchez","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0160","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-019-02633-0","article-title":"SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients","volume":"75","author":"Shi","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0170","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0175","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0180","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1212\/01.WNL.0000137051.33486.C7","article-title":"Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy","volume":"63","author":"Tan","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0190","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FPC.0b013e3283498131","article-title":"Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy","volume":"21","author":"Ufer","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0195","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2174\/13816128113199990462","article-title":"Role of monocarboxylate transporters in drug delivery to the brain","volume":"20","author":"Vijay","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0200","article-title":"Association of UGT2B7 and CaMK4 with response of valproic acid in Chinese children with epilepsy","author":"Wang","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0205","first-page":"1289","article-title":"Establishment of population pharmacokinetics model of valproic acid in Chinese children with epilepsy by using NLME program","volume":"35","author":"Wang","year":"2015","journal-title":"Chin. Hosp. Pharm. J."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00228-017-2395-z","article-title":"Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis","volume":"74","author":"Wang","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0215","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/tpj.2013.43","article-title":"SCN1A variations and response to multiple antiepileptic drugs","volume":"14","author":"Yip","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","article-title":"Polymorphisms of human cytochrome P450 2C9 and the functional relevance","volume":"278","author":"Zhou","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0225","first-page":"416","article-title":"ABCB1, ABCC2, SCN1A, SCN2A, GABRA1 gene polymorphisms and drug resistant epilepsy in the Chinese Han population","volume":"70","author":"Zhou","year":"2015","journal-title":"Die Pharmazie"},{"key":"10.1016\/j.eplepsyres.2020.106485_bib0230","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/jhg.2017.91","article-title":"The pharmacogenomics of valproic acid","volume":"62","author":"Zhu","year":"2017","journal-title":"J. Hum. Genet."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:43:55Z","timestamp":1760276635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121120305362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":46,"alternative-id":["S0920121120305362"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106485","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106485"}}